General Clinical Chemistry Analyzers and Accessories
Abcam V-9302, 5MG
MW 538.7 Da, Purity >=98%. A competitive antagonist of transmembrane glutamine flux, that selectively targets the amino acid transporter ASCT2 (SLC1A5). V-9302 inhibits ASCT2-mediated glutamine uptake (IC₅₀ = 9.6 μM) in HEK-293 cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Capivasertib (AZD5363), 100MG
MW 428.9 Da, Purity >95%. A novel pyrrolopyrimidine derivative. A potent inhibitor of all AKT isoforms, IC₅₀ <10 nM, with potential antineoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2940680 (Taladegib), 5MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK-690693 hydrochloride, ATP-competitive pan-Akt kinase inhibitor, 25MG
MW 425.5 Da, Purity >99%. Novel ATP-competitive pan-Akt kinase inhibitor (IC₅₀ values are 2, 13 and 9 nM for Akt1, 2 and 3 respectively). Also exhibits some inhibition of AMPK, PKA and PAK and PKC isoforms (IC₅₀ < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.
The product is subject to the following: Abcam Restricted Use Statement
Rarecyte RareCyte AccuCyte Blood Collection Tube, Sterile, 100-Pack
A pack of hundred sterile AccuCyte Blood Collection Tubes (BCTs). Contents in the tubes stabilize and preserve nucleated cells in whole blood.
Abcam SRT-3025 hydrochloride, 5MG
MW 606.2 Da, Purity >=98%. SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 50MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sitravatinib, 25MG
MW 629.7 Da, Purity =98%. Broad spectrum receptor tyrosine kinase inhibitor (e.g. Axl, c-Met, PDGFR, VEGFR, Ephrin receptor family, and FLT3). Better efficacy in mouse models than imatinib and crizotinib.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GW 6471, PPAR alpha antagonist, 5MG
MW 619.7 Da, Purity >98%. Potent PPAR alpha antagonist (IC₅₀ = 240 nM). Drives displacement of co-activators from PPAR alpha. Promotes recruitment of co-repressor proteins SMRT and NCoR to ligand binding domain. Inhibits cardiomyocyte differentiation in mouse embryonic stem cells. Causes reduced expression of cardiac sarcomeric proteins and specific genes in a time-dependent manner.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Prostaglandin A1, 5MG
MW 336.5 Da. Endogenous prostaglandin with diverse biological actions including anti-hypertensive, anti-inflammatory, anti-viral and anti-cancer properties.
The product is subject to the following: Abcam Restricted Use Statement
Abcam D-Gluconic acid, methyl ester, 50MG
MW 210.18 g/mol. Membrane permeant analog of D-gluconic acid. Useful as a component of cell culture media; enzymatic degradation of xylan and glucomannan; various pharmaceutical preparations; as well as an intermediate in carbohydrate based synthetic preparations of sugar derivatives.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LCL161, 100MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ispinesib (SB-715992), 5MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement